GlycoMimetics Inc (GLYC) - Financial and Strategic SWOT Analysis Review

March 2021 | 49 pages | ID: G8D3B2C0B27EN
GlobalData

Abstracts

GlycoMimetics Inc (GLYC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GlycoMimetics Inc (GlycoMimetics) is a clinical-stage biotechnology company that discovers, develops and commercializes small molecule drugs. The company’s pipeline products comprise uproleselan, rivipansel (GMI-1070), under phase III clinical trial is an anti-inflammatory compound to treat vaso-occlusive crisis of sickle cell disease and blood cancers. It is also designing galectin inhibitors for advancing treatment options of various diseases. GlycoMimetics designs and tests viral and bacterial entry inhibitors dendritic cell receptor. The company uses proprietary glycobiology technology to develop treatments for diseases. It also offers clinical research programs. GlycoMimetics is headquartered in Rockville, Maryland, the US.

GlycoMimetics Inc Key Recent Developments

Mar 02,2021: GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020
Feb 23,2021: GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2
Nov 06,2020: GlycoMimetics reports highlights and financial results for third quarter 2020
Jul 31,2020: GlycoMimetics reports highlights and financial results for second quarter 2020
May 01,2020: GlycoMimetics reports operational highlights and financial results for first quarter 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

GlycoMimetics Inc - Key Facts
GlycoMimetics Inc - Key Employees
GlycoMimetics Inc - Key Employee Biographies
GlycoMimetics Inc - Major Products and Services
GlycoMimetics Inc - History
GlycoMimetics Inc - Company Statement
GlycoMimetics Inc - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
GlycoMimetics Inc - Business Description
R&D Overview
GlycoMimetics Inc - Corporate Strategy
GlycoMimetics Inc - SWOT Analysis
SWOT Analysis - Overview
GlycoMimetics Inc - Strengths
GlycoMimetics Inc - Weaknesses
GlycoMimetics Inc - Opportunities
GlycoMimetics Inc - Threats
GlycoMimetics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
GlycoMimetics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 02, 2021: GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020
Feb 23, 2021: GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March
Nov 06, 2020: GlycoMimetics reports highlights and financial results for third quarter 2020
Jul 31, 2020: GlycoMimetics reports highlights and financial results for second quarter 2020
May 01, 2020: GlycoMimetics reports operational highlights and financial results for first quarter 2020
Feb 28, 2020: GlycoMimetics reports highlights and financial results for fourth quarter and year-end 2019
Jan 07, 2020: Apollomics buys AML programme rights in Greater China

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

GlycoMimetics Inc, Key Facts
GlycoMimetics Inc, Key Employees
GlycoMimetics Inc, Key Employee Biographies
GlycoMimetics Inc, Major Products and Services
GlycoMimetics Inc, History
GlycoMimetics Inc, Key Competitors
GlycoMimetics Inc, Ratios based on current share price
GlycoMimetics Inc, Annual Ratios
GlycoMimetics Inc, Annual Ratios (Cont...1)
GlycoMimetics Inc, Interim Ratios
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
GlycoMimetics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

GlycoMimetics Inc, Performance Chart (2016 - 2020)
GlycoMimetics Inc, Ratio Charts
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021